Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Genus plc (GNSN) Stock Price & Analysis

GNSN Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
MXN 37.28B
Enterprise Value
MXN 1.51B
Total Cash (Recent Filing)
MXN 43.70M
Total Debt (Recent Filing)
MXN 107.50M
Price to Earnings (P/E)
5.3
Beta
N/A
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet Deleveraging

Material debt reduction and higher equity have strengthened Genus's financial resilience and lowered leverage risk. A healthier capital structure should preserve flexibility to fund research, support customers, pursue growth opportunities, and maintain shareholder returns through the next several quarters.

Operating Profit And Margin Growth

Broad-based operating profit and margin improvement indicates that Genus is converting revenue into earnings more efficiently across its businesses. Sustained productivity benefits, especially from ABS's improvement program, can support stronger earnings quality and investment capacity over time.

PRP Commercialization Progress

Regulatory progress for PRRS-resistant pig technology creates a potentially differentiated growth platform beyond Genus's established genetics portfolio. Additional approvals and early commercialization can build customer, supply, and data foundations for a new recurring revenue opportunity.

Bears Say

North American Disease Pressure

Livestock disease pressure is directly reducing customer production and royalty-linked revenue in North America. Management expects the headwind to continue into the first half of FY 2027, so recovery depends partly on normalization of operating conditions outside Genus's immediate control.

Weak Dairy Market Conditions

Persistent dairy-market weakness can constrain farmer spending and reduce demand for bovine genetics, limiting ABS volume growth even where Sexcel performs well. Continued depressed prices may therefore delay a broader recovery in the segment and make near-term growth more uneven.

Volatile Earnings Quality

The sharp profit increase despite lower revenue raises questions about how much of the improvement is repeatable operating performance. Earlier margin compression and inconsistent profitability make future earnings less predictable, requiring continued execution to demonstrate durable underlying progress.

Genus plc News

GNSN FAQ

What is Genus plc’s market cap?
Genus plc’s market cap is Mex$37.28B.
When is Genus plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genus plc’s earnings last quarter?
Genus plc released its earnings results on Sep 10, 2026. The company reported Mex$97.186 earnings per share for the quarter.
Is Genus plc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Genus plc pay dividends?
Genus plc does not currently pay dividends.
What is Genus plc’s EPS estimate?
Genus plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus plc have?
Genus plc has 65,225,365 shares outstanding.
What happened to Genus plc’s price movement after its last earnings report?
Genus plc reported an EPS of Mex$97.186 in its last earnings report. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Genus plc?
Currently, no hedge funds are holding shares in MX:GNSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology